Ganaplacide
- Generic Name
- Ganaplacide
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23F2N5O
- CAS Number
- 1261113-96-5
- Unique Ingredient Identifier
- 85VMN9JU7A
- Background
Ganaplacide is under investigation in clinical trial NCT03167242 (Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria).
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05330273
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- Combination Product: Lumefantrine
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05236530
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT05084651
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
Phase 2
Recruiting
- Conditions
- Uncomplicated Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 295
- Registration Number
- NCT04546633
- Locations
- 🇲🇱
Novartis Investigative Site, Sotuba, Mali
Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT04072302
- Locations
- 🇺🇸
Novartis Investigative Site, Seattle, Washington, United States
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Phase 2
Completed
- Conditions
- Acute Uncomplicated Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 524
- Registration Number
- NCT03167242
- Locations
- 🇻🇳
Novartis Investigative Site, Binh Phuoc Province, VNM, Vietnam
Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01753323
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath